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In  Indonesia,  avian  inﬂuenza  A(H5N1)  virus  started  to spread  in  humans  in  June  2005,  with  an  alarming
case-fatality  rate  of  more  than  80%.  Considering  that  global  inﬂuenza  vaccine  production  capacity  would
barely  have  covered  10%  of  the  world’s  pandemic  vaccine  needs,  and that  countries  with  no  production
facilities  or prearranged  contracts  would  be  without  access  to  a  vaccine,  the  Government  of  Indonesia
embarked  on  a  programme  to  increase  its  readiness  for  a future  inﬂuenza  pandemic.  This  included  the
domestic  production  of  inﬂuenza  vaccine,  which  was  entrusted  to  Bio  Farma.
This  health  security  strategy  consists  of developing  trivalent  inﬂuenza  vaccine  production  capacity  in
order  to be  able  to convert  immediately  to monovalent  production  of  up  to 20 million  pandemic  doses
for  the  Indonesian  market  upon  receipt  of  the  seed  strain  from  the  World  Health  Organization  (WHO).
For  this  purpose,  a  dedicated  production  facility  is  being  constructed  within  the  Bio Farma  premises  in
Bandung.As  an  initial  stage  of inﬂuenza  vaccine  development,  imported  seasonal  inﬂuenza  bulk has  been  formu-
lated  and  ﬁlled  in  the  Bio  Farma  facility.  Following  three  consecutive  batches  and  successful  clinical  trials,
the  product  was  licensed  by the  Indonesian  National  Regulatory  Authority  and  distributed  commercially
for  the  Hajj  programme  in  2009.  With  continued  support  from  its technology  transfer  partners,  Bio  Farma
is  now  advancing  with  the  development  of  upstream  processes  to  produce  its  own  bulk  for seasonal  and
pandemic  use.
. Introduction
The highly pathogenic avian inﬂuenza outbreak in Asia started
preading in Indonesia in June 2005, with a case-fatality rate of
ore than 80%. Although antiviral drugs and personal protective
easures can contain such a spread to some extent, only an effec-
ive pandemic vaccine can protect the millions of vulnerable human
ives from an inﬂuenza virus of this severity. At that time, the maxi-
um global capacity for monovalent inﬂuenza vaccine production
as a fraction of the doses needed to vaccinate the entire popula-
ion, and countries in South-East Asia with no production facilities
r prearranged contracts would be without access to vaccine for
nything up to a year or more [1].
The Government of Indonesia therefore embarked on a pro-
ramme  to increase its readiness for a future inﬂuenza pandemic,
ncluding the domestic production of inﬂuenza vaccine which was
ntrusted to its long-established manufacturer of human vaccines,
io Farma. This health security strategy consisted of the develop-
ent of capacity for trivalent seasonal inﬂuenza vaccine production
n order to be able to convert immediately to monovalent pandemic
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production of up to 20 million doses for the Indonesian market
upon receipt of the seed strain from the World Health Organization
(WHO).
Founded over 120 years ago, Bio Farma is the sole supplier of
traditional EPI (Expanded Programme on Immunization) vaccines
for the national immunization programme. The company facilities
meet the highest standards of Good Manufacturing Practices (GMP)
and quality assurance as witnessed by many of its vaccines pre-
qualiﬁed by WHO. Bio Farma is one of the largest producers of
human vaccines in Asia, and is also well versed in international
vaccine technology transfer partnerships such as from Japan, the
Netherlands and the USA.
From  2007, to complement signiﬁcant multi-year Government
support, Bio Farma was  successful in identifying technical and
ﬁnancial assistance to achieve this ambitious goal. An agreement
was signed with Biken Institute, Japan covering the transfer of tech-
nology to formulate and ﬁll imported egg-based inactivated split
trivalent inﬂuenza bulk vaccine and progressively the upstream
process technology and quality control for antigen production at
Bio Farma. For this purpose, a dedicated production facility is being
Open access under CC BY-NC-ND license.constructed within the Bio Farma premises in Bandung.
In  parallel, Bio Farma was selected as a grantee of the WHO
inﬂuenza vaccine technology transfer initiative, which sought to
increase access of developing countries to a pandemic inﬂuenza
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Table 1
Experimental batches of H1N1 monovalent bulk in developing the upstream process.
No. of batches Seed strain Egg scale Date
2 A/California/7/2009 (H1N1)v-like IVR-153 1 000 Q3 2009 From NISBC, propagated and distributed in aliquot
at  Airlangga University BSL3+ facility
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accine through domestic production capacity. The WHO  seed
unding for transfer of the technology, procurement of equipment
or quality control and production, and formulation and ﬁlling
raining for seasonal vaccine imported from Biken, complemented
he ﬁnancial contributions of Bio Farma and the Indonesian Gov-
rnment.
This article describes the progress made towards the following
our objectives of the project: (i) technology transfer for the pro-
uction of inﬂuenza vaccine; (ii) installation and operationalization
f a formulation and ﬁlling unit; (iii) registration in Indonesia
f seasonal vaccine developed from imported bulk antigen; (iv)
roduction of bulk inactivated inﬂuenza antigen for seasonal and
andemic use.
.  Downstream formulation and ﬁlling capacity
Since the existing formulation and ﬁlling lines at Bio Farma were
ully occupied for routine vaccine production, a new unit was estab-
ished and fully equipped.
Following  the transfer from Biken, Japan of the technol-
gy to formulate, ﬁll and quality control trivalent seasonal
nﬂuenza vaccine, three monovalent bulks each of the fol-
owing strains were received from Biken in December 2007:
/Hiroshima/52/205 (H3N2); A/Solomon Islands/3/2006 (H1N1);
/Malaysia/2506/2004.
In 2008, three consecutive batches were successfully produced
rom the imported bulk antigen in two presentations: single-dose
mpoules for use in clinical trials, and multi-dose vials for stability
tudies. Within 1 year of the start of the project, candidate seasonal
nﬂuenza vaccine lots prepared for clinical trial were approved
y the National Agency of Drug and Food Control (NADFC) in
ndonesia. The results of analyses performed in Indonesia on clinical
rial lots were conﬁrmed in samples sent to Biken.
In response to a request from NADFC, Bio Farma also carried
ut a prelicensure bridging study to assess the safety and immuno-
enicity of the vaccine in 405 adolescents and adults (12–64 years
ld), randomly assigned to above three bulk batches. A single 0.5 mL
ose was administered intramuscularly and blood samples taken
efore and 28 days after immunization. Results showed that the
accine induced high antibody titres against inﬂuenza antigens in
ll subjects (≥1:40 haemagglutination inhibition to A/Hiroshima,
/Solomon Island and B/Malaysia strains 97.8%, 98.2% and 95.5%,
espectively; p = 0.025). The geometric mean titres after immuniza-
ion increased (A/Hiroshima: 66.16–323.37; A/Solomon Islands:
1.89–554.26; B/Malaysia: 24.02–231.83), and subjects with a
ourfold increase in antibody titre were 61.2%; 85.5%; 81.5%, respec-
ively. All vaccines were well tolerated and no serious adverse
vents were noted after 28 consecutive days of observation after
mmunization.
Results of these studies showed that the vaccine to be
mmunogenic and safe. The NADFC therefore issued marketing
uthorization and Bio Farma’s seasonal inﬂuenza vaccine Flubio®ecame the ﬁrst licensed product of the WHO  technology transfer
nitiative in June 2009. Some 165,000 doses were produced for com-
ercial distribution focusing principally on mass immunization of
ajj pilgrims. Until such time as Bio Farma is able to produce its own Q4 2009 From  NISBC, propagated and distributed in Bio
Farma BSL2+ facility using BSL3+ practices Q2 2010
 Q4 2010 Experimental batches leading to consistency lots
seasonal  (and ultimately pandemic) antigen, bulk seasonal vaccine
supplies will continue to be imported from Biken Institute in Japan,
for which a commercial agreement has been signed.
3.  Upstream development and production of inactivated
inﬂuenza vaccine
The  majority of the critical equipment for the preparation of
seed lots, upstream process and quality control in pilot scale has
been received.
In  2008, Bio Farma started the preliminary development of the
upstream process for seasonal inﬂuenza vaccine, and by April 2009
had produced three batches of seasonal bulk antigen derived from
A/Solomon Islands/3/2006 IVR-145 seed strain at 1 000 egg scale.
A Technical Collaboration and License Agreement was signed
between Bio Farma and Biken Institute of Japan in December 2009
for the transfer of inﬂuenza vaccine upstream production process.
This was implemented through the training of Bio Farma staff at
the Biken campus and follow-up training in Indonesia (see Sec-
tion 4 below). Technology transfer of concentrated bulk preparation
comprises the upstream process technology and quality control of
seasonal inﬂuenza vaccine, i.e. seed preparation and virus cultiva-
tion up to the inactivation processes.
3.1. Pandemic inﬂuenza—product characterization and
optimization
In  July 2009, following the onset of the A(H1N1) inﬂuenza pan-
demic, Bio Farma switched its attention to the development of a
vaccine against this novel strain and by November 2010 a total
of 20 lots had been produced (Table 1). Of the latest nine batches
of A(H1N1) derived from A/California/7/2009 (H1N1)v-like NYMC
179A, the ﬁrst three were used to familiarize Bio Farma opera-
tors with the process. Thanks to this experience and hands-on
guidance from Biken experts, the next batches showed increasing
consistency (Table 2), and it is expected that by early 2011, three
consecutive and consistent batches will have been produced to be
formulated as monovalent pandemic ready-ﬁlled bulk.
3.2.  Construction of an industrial scale antigen production facility
Within its overall inﬂuenza pandemic preparedness plan, the
Indonesian Ministry of Health decided to set up a manufactur-
ing facility for egg-based inﬂuenza vaccines against wild-type
inﬂuenza virus strains. The project comprises the whole manu-
facturing process including bulk antigen production, formulation,
ﬁlling, laboratory quality control facilities, as well as an inde-
pendent chicken farm to produce embryonated eggs. Signiﬁcant
progress had made in the physical execution of the BSL3+ building
within the Bio Farma complex in Bandung. Following a consulta-
tive process among all stakeholders, the design, layout and ﬁnal
operating spaces of the three ﬂoors of the building were approved
and the building is nearing physical completion. Process equip-
ment will then be installed and connected to utility and service
distribution points. Following operational and performance qual-
iﬁcation, GMP  and building monitoring systems and the training
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Table  2
Consistency of experimental batches of 10 000 egg scale monovalent bulk using seed
strain of A/California/7/2009 (H1N1)v-like NYMC X-179A.
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tesults show increasing consistency since batch 2. Analysis of batches 6–9 are
xpected  to be completed by January 2011.
f staff in all standard operating and maintenance procedures, it is
stimated that the plant will be fully operational during 2012.
.3.  Supply of clean eggs
Bio  Farma has entered an arrangement with the supplier of
iken in Japan – HokoEn – for  the supply of embryonated eggs.
owever, in order to move towards self-sufﬁciency in the event
f a pandemic, and given Bio Farma’s extensive experience in han-
ling speciﬁc pathogen-free eggs for measles vaccine, the company
nitiated the establishment of its own chicken farm within its exist-
ng 28 ha animal breeding farm in Cisarua, Lembang, some 25 km
rom Bandung. The farm will contain a rearing house with a capac-
ty for 16 500 hens and three production houses for 16 500 hens
ach, sufﬁcient to produce >4 million eggs/year, i.e. to meet current
roduction projections. Bio Farma will also enter into negotiations
ith other egg producers in Indonesia to ensure an adequate supply
f clean eggs in the event of a pandemic. Construction of the farm
s due for completion in April 2011 and, following quality control
nd the importation of chickens, embryonated eggs are expected
o become available during the second half of 2011.
.  Training
To ensure the efﬁciency of the technology transfer project, staffs
t Bio Farma have been fully trained in the management, production
nd quality control techniques related to inﬂuenza vaccine, both on
nd off site.
At  the start of the inﬂuenza project at Bio Farma in
ugust–September 2007, four staff were invited to Biken Institute
n Japan for 2 weeks’ training in the formulation and quality con-
rol of seasonal inﬂuenza vaccine, including regulatory aspects. This
as followed in April 2008 by a 1-week course at the National
nstitute for Biological Standards and Control in the United King-
om to learn the techniques for carrying out speciﬁc assays for
nﬂuenza vaccine testing, such as single radial immunodiffusion
SRID) assays and testing for endotoxin. Also under the auspices
f the WHO  technology transfer project, Bio Farma quality con-
rol staff joined a 1-week workshop on quality assurance and GMP
elated to inﬂuenza vaccine at the Netherlands Vaccine Institute
NVI) in Bilthoven, the Netherlands in June 2009. The produc-
ion team also visited NVI to attend a 3-week training course on 29S (2011) A22– A25
inﬂuenza  production and quality control. Participants learnt ﬁrst-
hand all aspects of the inﬂuenza vaccine production process as well
as the quality control and release assays speciﬁc to individual pro-
cesses such as 50% of the egg infectious dose (EID50), SRID, and tests
for ovalbumin, neuraminidase, endotoxin and sucrose gradients.
For  the upstream process, 11 personnel from Bio Farma par-
ticipated in a 3-week training course in Japan in April 2010 on
preparation of concentrated bulk and quality control of seasonal
inﬂuenza vaccine. Staffs became skilled in seed preparation, virus
cultivation up to the inactivation processes of whole virus tech-
nology, and in the operation and maintenance of the production
equipment. Technical training was  also conducted at the HokoEn
facility in Japan on embryonated egg production covering activ-
ities of the rearing house, production house and primary setter.
Experts from Biken have also visited Bandung on several occasions
to provide guidance at critical moments in the development of the
project.
Bio Farma has received valuable advice from WHO, its Tech-
nical Advisory Group and its National Regulatory Authority during
technical and monitoring visits to the site, which enabled the imple-
mentation of any corrective action in a timely manner.
5.  The future
5.1.  Cell-based inﬂuenza vaccine production
Bio Farma chose egg-based inﬂuenza vaccine technology in
order to meet the need to produce and license a vaccine as rapidly
as possible in view of an impending inﬂuenza pandemic threat,
and will continue to pursue this technology. However, continu-
ous cell lines for the production of viral vaccines offer advantages
such as the opportunity to use fully characterized and standard-
ized cells and the ability to rapidly produce a pandemic vaccine.
Bio Farma therefore plans to develop a cell-based inﬂuenza vac-
cine as part of its research and development portfolio, and has been
fortunate to access this novel production technology through an
agreement with the Department of Microbiology at the Iwate Med-
ical University, Japan. Development of the modiﬁed MDCK-derived
technology will involve cell-based up-scaling process and viral seed
sensitivity; cell bank certiﬁcation; viral puriﬁcation; vaccine for-
mulation and small-scale production; immunogenicity studies. Bio
Farma has already embarked on the ﬁrst phase of the project by
conducting a successful preliminary safety test of the cell-based
viral cultivation system.
5.2.  Adjuvanted pandemic inﬂuenza vaccine
Increasingly, vaccines are being formulated using safe and effec-
tive adjuvants since they have been proven to induce immunity at
signiﬁcantly lower levels of antigen. This dose-sparing capacity is
thus of particular interest for mass immunization campaigns and
in a pandemic situation. Bio Farma was selected as the ﬁrst ben-
eﬁciary of the Vaccine Formulation Laboratory, a new initiative to
transfer the technology for a generic oil-in-water adjuvant along
with expertise in its formulation with inﬂuenza vaccine based at
the University of Lausanne, Switzerland.
6. Discussion
Highly pathogenic avian inﬂuenza viruses continue to pose a
threat in Indonesia. In September 2010, two  patients were diag-
nosed positive for A(H5N1), and a further suspected case of this
strain was in intensive care in November 2010 [2].
Bio  Farma has proven its capability to manufacture seasonal
inﬂuenza vaccine to the highest international safety and efﬁcacy
accine
s
t
t
r
S
H
d
I
w
u
n
s
T
e
e
7
a
s
i
b
m
h
i
[M. Suhardono et al. / V
tandards, in record time. The company was also on track to be able
o produce a pandemic vaccine, which is the ultimate objective of
he project in Indonesia. However, inﬂuenza vaccination is not cur-
ently part of the routine immunization programme in Indonesia.
ince 2009, Bio Farma has provided seasonal vaccine to immunize
ajj and Umrah pilgrims to Mecca, but this may  not be a sufﬁcient
omestic market to sustain the manufacture of inﬂuenza vaccine.
n addition, the annual pilgrimage follows the lunar calendar, and
ill thus become challenging for the inﬂuenza production sched-
le. Options such as increasing the domestic market, producing for
eighbouring countries, or supplying northern and southern hemi-
phere formulations for other parts of the world, may  be explored.
his will require political and international support to present the
vidence on which the Government of Indonesia may  make cost-
ffective decisions.
.  Conclusion
Bio Farma has made signiﬁcant progress towards its goal to be
ble to manufacture a pandemic inﬂuenza vaccine for the health
ecurity of the Indonesian people. This has been possible due to
ts solid corporate vision, qualiﬁed and committed workforce, and
road, inclusive collaboration with all stakeholders. The commit-
ent of a technology partner, Biken Institute of Japan, and of WHO
ave been instrumental in ensuring Bio Farma’s self-reliance in this
ssue of immense public health importance.
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